Cerevance is a new pharmaceutical company focused on central nervous system diseases. The Company's strengths include a powerful technology platform, a pipeline of novel discovery-stage and clinical-stage compounds and a proven team. Cerevance believes that it is well positioned to deliver life-changing therapeutics for patients who have brain-related disorders.
Besides having a powerful discovery platform that may reveal new insights about brain diseases, Cerevance is already advancing preclinical and clinical programs for: parkinson's disease, schizophrenia, cognitive impairment and addictive disorders.
Cerevance total Funding
Cerevance latest funding size
Time since last funding
|2 months ago|
|Takeda Ventures, Bill Gates, Foresite Capital, Lightstone Ventures, Takeda Pharmaceutical, GV, SV Health Investors, Dementia Discovery Fund|
Cerevance has 116 Twitter Followers. The number of followers has increased 16.7% month over month and increased 41.2% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Cerevance founded?
Cerevance was founded in 2016.
Who are Cerevance key executives?
Cerevance's key executives are Brad Margus, Nathaniel Heintz and Mark Carlton.
Who are Cerevance competitors?
Competitors of Cerevance include RespireRx Pharmaceuticals, Futura Medical and IntelGenx.
Where is Cerevance headquarters?
Cerevance headquarters is located at One Marina Park Drive Suite 1410, Boston.
Where are Cerevance offices?
Cerevance has offices in Boston and Milton.
How many offices does Cerevance have?
Cerevance has 2 offices.
Receive alerts for 300+ data fields across thousands of companies